BSc (Hons), GradDipEpi, MAICD
DIRECTOR & PARTNER
George is a Health Economist, Pricing and Reimbursement and Strategic Market Access Expert with over 25 years in the healthcare industry in both Australia and USA. An experienced key speaker and commentator, his current leadership roles include chairman of ARCS Australia and Lecturer at UNSW, Pharmaceutical Medicine.
He has worked at both local and international levels at senior levels in Australia, Belgium and the United States including Pharmacia, Johnson & Johnson, Schering-Plough and Merck. George established Emerald Corporate Group and has since assisted multiple healthcare companies to successfully gain market access for innovative technologies.
George is expert in developing health economic and reimbursement strategies, strategic pricing initiatives, early assessment of commercial opportunities and preparation of health economic submissions to reimbursement authorities. George received his BSc [Hons] from the University of Sydney and Grad Dip Epi (Pharmacoepi) from the University of Newcastle. He is a current member of ISPOR and the current Treasurer of ISPOR Australia. He is an active member of ARCS (Australasian Society of Regulatory and Clinical Scientists), HTAi (Health Technology Assessment International), iHEA (International Health Economics Association) and a member of the AICD (Australian Institute of Company Directors).
BA Econ (Hons), MSc (Health Econ)
DIRECTOR & PARTNER
Michael has specialised in health economics and health technology assessment for 20 years, graduating in 1989 at the University of York, UK. His public sector experience included appointment in 1992 as Deputy Director of the Pharmaceutical Evaluation Section in the Federal Health Department. He was part of a multi-disciplinary team responsible for implementing the Australian Pharmaco-economic Guidelines, advising the decision-making committees and policy development. In 1995, he co-founded the M-TAG consultancy in Sydney and in 2000 led the company’s UK office where he gained experience in the NICE system as well as other European systems. In 2005, M-TAG was acquired by IMS Health and Michael gained a wider role within the consultancy and patient data areas of the new business focusing on larger projects. Michael has delivered projects to local, regional and head offices of the larger Pharma and medical technology companies, hence has a deep understanding of the commercial environment.
He has worked across most therapy areas and is published widely in the area of economic evaluation and health technology assessment and spoken at a number of international venues. His strengths are in demonstrating the value of health technologies with the broad range of available tools in health economics and outcomes research. A key focus from Michael is on the credibility and quality of the supporting data. He also has solid staff and project management background and has advised senior industry personnel in several countries. Key services include assessing feasibility for value-for-money case, planning research activities and data collection, design and review of models/submissions/dossiers and design and review of primary data collection studies (e.g. preference studies, patient management surveys, database studies).
BApplSci, MBA, MSc (Health Econ)
DIRECTOR & PARTNER
University of York trained with over 25 years’ experience in health economics who has combined a career in both the pharmaceutical industry and academia. Detailed technical knowledge and broad senior management experience in market access activities in both Australia and Asia-Pacific (particularly Japan) including reimbursement and pricing, corporate and government affairs, policy, regulatory and early and new product commercialisation. Steve has held positions at management team level for 15 years in Australia with Board experience at a biotechnology company.
Steve has extensive experience in building and reorganising market access, new product commercialisation and real-world evidence generation processes and capabilities across numerous companies and markets leading to successful reimbursement and pricing outcomes. Over the last decade Steve has led the Janssen Australia Integrated Market Access team and Janssen has been the most successful company in Australia in achieving market access based on a number of indicators including reimbursement success and time to market.
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.